FDA approves generic epilepsy drug from Acella

Acella Pharmaceuticals wins approval for gabapentin oral solution

ATLANTA — The Food and Drug Administration has approved a generic drug for epilepsy made by Acella Pharmaceuticals, the company said Wednesday.

Acella announced the approval of gabapentin oral solution in the 250-mg-per-5-mL strength. The drug is a generic version of Parke Davis' Neurontin.

"Acella looks forward to adding gabapentin oral solution to our existing line of products as we continue our product development strategy of gaining approval from the FDA and global regulatory agencies for the [abbreviated new drug applications] and [new drug applications] in our pipeline," Acella VP and head of research and development Allen Fields said, referring to the applications used by drug makers to get FDA approval for generic and branded drugs, respectively.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

Login or Register to post a comment.